NVIDIA Likely To Report Lower Quarterly Earnings, Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts – NVIDIA (NASDAQ:NVDA)

nvidia corporation NVDA is scheduled to release its financial results for the quarter at the latest after the closing bell on February 22, 2023.

Analysts expect the company to post quarterly earnings of $0.81 per share, down from $1.32 per share in the year-ago period. The company is likely to report revenue of $6.01 billion for the quarter.

Shares of NVIDIA fell 3.4% to close at $206.55 on Tuesday and fell 0.8% in today’s pre-market trading session.

Benzinga readers can access the latest analyst ratings analyst stock rating Page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s take a look at how Benzinga is the most accurate Analysts rated the company in the recent period.

• oppenheimer Analyst Patrick Scholes maintained an Outperform rating and raised the price target for February 21, 2023 from $225 to $250. This analyst sees an upside of about 21% in the company’s stock and has an accuracy rate of 68%.
• Morgan Stanley Analyst Joseph Moore maintained an equal-weight rating on February 21, 2023 and raised the price target to $246 from $175. This analyst sees approximately 19% upside in the company’s stock and has an accuracy rate of 67%.
• Stifel Analyst Reuben Roy maintained a Hold rating and raised the price target for February 21, 2023 from $175 to $207. This analyst sees approximately 0.2% upside in the company’s stock and has an accuracy rate of 84%.
• BMO Capital Analyst Ambrish Srivastava maintained Outperform rating on February 21, 2023 and raised the price target to $240 from $210. This analyst sees more than 16% upside in the company’s stock and has an 82% accuracy rate.
• keybank Analyst John Vinh maintained an Overweight rating and raised the February 17, 2023 price target from $220 to $280. This analyst sees roughly 35% upside in the company’s stock and has an accuracy rate of 71%.

Read it further: $3M Bet on This Biotechnology Stock? Check Out These 3 Penny Stock Insiders Are Buying